Aligos Therapeutics (ALGS) Other Accumulated Expenses (2019 - 2026)

Aligos Therapeutics has reported Other Accumulated Expenses for 8 years, with the latest figure at $4.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 10.43% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (up 10.43% YoY), and the FY2025 full-year result was $3.2 million, up 59.11% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $4.3 million, up from $3.2 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $6.6 million in Q4 2023, with the low at $856000.0 in Q2 2022.
• Historically, Other Accumulated Expenses has averaged $2.7 million across 5 years, with a median of $2.7 million in 2024.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses jumped 350.31% — and 2024, when it plunged 69.21%.
• Aligos Therapeutics' Other Accumulated Expenses stood at $1.5 million in 2022, then surged by 350.31% to $6.6 million in 2023, then sank by 69.21% to $2.0 million in 2024, then soared by 59.11% to $3.2 million in 2025, then soared by 30.96% to $4.3 million in 2026.
• The last three Other Accumulated Expenses figures came in at $4.3 million (Q1 2026), $3.2 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.